Identification
- Generic Name
- Farnesyl thiopyrophosphate
- DrugBank Accession Number
- DB04695
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Farnesyl thiopyrophosphate (DB04695)
- Weight
- Average: 398.392
Monoisotopic: 398.108182342 - Chemical Formula
- C15H28O6P2S
- Synonyms
- Farnesyl thiodiphosphate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGeranylgeranyl pyrophosphate synthase Not Available Humans UMevalonate kinase Not Available Humans UDehydrosqualene synthase Not Available Staphylococcus aureus UDitrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific) Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcrivastine The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Acrivastine. Adenosine The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Farnesyl thiopyrophosphate. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Farnesyl thiopyrophosphate. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Farnesyl thiopyrophosphate. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Farnesyl thiopyrophosphate. Amifampridine The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amifampridine. Amiodarone The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amisulpride. Amitriptyline The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amitriptyline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Sesquiterpenoids
- Direct Parent
- Sesquiterpenoids
- Alternative Parents
- Organic phosphoric acids and derivatives / Sulfenyl compounds / Organothiophosphorus compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Farsesane sesquiterpenoid / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organosulfur compound / Organothiophosphorus compound / Sesquiterpenoid / Sulfenyl compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- MYMLCRQRXFRQGP-YFVJMOTDSA-N
- InChI
- InChI=1S/C15H28O6P2S/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-24-23(19,20)21-22(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H,19,20)(H2,16,17,18)/b14-9+,15-11+
- IUPAC Name
- {[hydroxy({[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl})phosphoryl]oxy}phosphonic acid
- SMILES
- [H]\C(CC\C(C)=C(/[H])CSP(O)(=O)OP(O)(O)=O)=C(\C)CCC=C(C)C
References
- General References
- Not Available
- External Links
- PubChem Compound
- 657041
- PubChem Substance
- 46506151
- ChemSpider
- 571259
- ZINC
- ZINC000012504468
- PDBe Ligand
- FPS
- PDB Entries
- 1x06 / 1x08 / 2e8t / 2r42 / 3q78 / 3sae / 3vkb / 3vzz / 3w00 / 3w7f … show 16 more
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.138 mg/mL ALOGPS logP 2.44 ALOGPS logP 4.11 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 2.03 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 104.06 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 103.23 m3·mol-1 Chemaxon Polarizability 40.62 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6707 Blood Brain Barrier + 0.7849 Caco-2 permeable - 0.5989 P-glycoprotein substrate Substrate 0.5222 P-glycoprotein inhibitor I Non-inhibitor 0.7409 P-glycoprotein inhibitor II Non-inhibitor 0.7184 Renal organic cation transporter Non-inhibitor 0.9272 CYP450 2C9 substrate Non-substrate 0.7724 CYP450 2D6 substrate Non-substrate 0.8188 CYP450 3A4 substrate Non-substrate 0.5454 CYP450 1A2 substrate Non-inhibitor 0.7732 CYP450 2C9 inhibitor Non-inhibitor 0.7454 CYP450 2D6 inhibitor Non-inhibitor 0.8731 CYP450 2C19 inhibitor Non-inhibitor 0.7273 CYP450 3A4 inhibitor Non-inhibitor 0.8392 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8597 Ames test Non AMES toxic 0.7158 Carcinogenicity Non-carcinogens 0.5926 Biodegradation Ready biodegradable 0.7134 Rat acute toxicity 2.7904 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7679 hERG inhibition (predictor II) Non-inhibitor 0.84
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Metal ion binding
- Specific Function
- Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins.
- Gene Name
- GGPS1
- Uniprot ID
- O95749
- Uniprot Name
- Geranylgeranyl pyrophosphate synthase
- Molecular Weight
- 34870.625 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Mevalonate kinase activity
- Specific Function
- May be a regulatory site in cholesterol biosynthetic pathway.
- Gene Name
- MVK
- Uniprot ID
- Q03426
- Uniprot Name
- Mevalonate kinase
- Molecular Weight
- 42450.475 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Staphylococcus aureus
- Pharmacological action
- Unknown
- General Function
- Transferase activity, transferring alkyl or aryl (other than methyl) groups
- Specific Function
- Catalyzes the head-to-head condensation of two molecules of farnesyl diphosphate (FPP) into the colorless C(30) carotenoid dehydrosqualene (4,4'-diapophytoene). This is the initial step in the bios...
- Gene Name
- crtM
- Uniprot ID
- A9JQL9
- Uniprot Name
- Dehydrosqualene synthase
- Molecular Weight
- 34312.78 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Magnesium ion binding
- Specific Function
- Generates ditrans,octacis-undecaprenyl pyrophosphate (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid in the biosynthesis of...
- Gene Name
- ispU
- Uniprot ID
- P60472
- Uniprot Name
- Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific)
- Molecular Weight
- 28443.92 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 11, 2007 17:49 / Updated at June 12, 2020 16:52